Literature DB >> 11584373

Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection.

H Bantel1, A Lügering, C Poremba, N Lügering, J Held, W Domschke, K Schulze-Osthoff.   

Abstract

Hepatitis C virus (HCV) infection is a major cause of liver disease characterized by inflammation, cell damage, and fibrotic reactions of hepatocytes. Apoptosis has been implicated in the pathogenesis, although it is unclear whether proteases of the caspase family as the central executioners of apoptosis are involved and how caspase activation contributes to liver injury. In the present study, we measured the activation of effector caspases in liver biopsy specimens of patients with chronic HCV infection. The activation of caspase-3, caspase-7, and cleavage of poly(ADP-ribose)polymerase (PARP), a specific caspase substrate, were measured by immunohistochemistry and Western blot analysis by using antibodies that selectively detect the active truncated, but not the inactive precursor forms of the caspases and PARP. We found that caspase activation was considerably elevated in liver lobules of HCV patients in comparison to normal controls. Interestingly, the immunoreactive cells did yet not reveal an overt apoptotic morphology. The extent of caspase activation correlated significantly with the disease grade, i.e., necroinflammatory activity. In contrast, no correlation was observed with other surrogate markers such as serum transaminases and viral load. In biopsy specimens with low activity (grade 0) 7.7% of the hepatocytes revealed caspase-3 activation, whereas 20.9% of the cells stained positively in grade 3. Thus, our results suggest that caspase activation is involved in HCV-associated liver injury. Moreover, measurement of caspase activity may represent a reliable marker for the early detection of liver damage, which may open up new diagnostic and therapeutic strategies in HCV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584373     DOI: 10.1053/jhep.2001.28229

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet.

Authors:  Michael K Pickens; Hisanobu Ogata; Russell K Soon; James P Grenert; Jacquelyn J Maher
Journal:  Liver Int       Date:  2010-06-08       Impact factor: 5.828

2.  Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Authors:  A B Jazwinski; A J Thompson; P J Clark; S Naggie; H L Tillmann; K Patel
Journal:  J Viral Hepat       Date:  2011-11-24       Impact factor: 3.728

3.  Apoptosis in chronic viral hepatitis parallels histological activity: an immunohistochemical investigation using anti-activated caspase-3 and M30 cytodeath antibody.

Authors:  Jo L McPartland; Muna Ali Guzail; Charles H Kendall; James Howard Pringle
Journal:  Int J Exp Pathol       Date:  2005-02       Impact factor: 1.925

Review 4.  Apoptosis: a mechanism of acute and chronic liver injury.

Authors:  M E Guicciardi; G J Gores
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

5.  Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice.

Authors:  Wing-Kin Syn; Liu Yang; Dian Jung Chiang; Yue Qian; Youngmi Jung; Gamze Karaca; Steve S Choi; Rafal P Witek; Alessia Omenetti; Thiago A Pereira; Anna Mae Diehl
Journal:  Liver Int       Date:  2009-04-20       Impact factor: 5.828

6.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

Review 7.  Hepatitis C virus infection and apoptosis.

Authors:  Richard Fischer; Thomas Baumert; Hubert-E Blum
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

8.  Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy.

Authors:  Burkhard J Manfras; Hans Weidenbach; Karl-Heinz Beckh; Peter Kern; Peter Möller; Guido Adler; Thomas Mertens; Bernhard O Boehm
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

Review 9.  Caspase inhibitors for the treatment of hepatitis C.

Authors:  Howard C Masuoka; Maria Eugenia Guicciardi; Gregory J Gores
Journal:  Clin Liver Dis       Date:  2009-08       Impact factor: 6.126

10.  Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway.

Authors:  Lin Deng; Tetsuya Adachi; Kikumi Kitayama; Yasuaki Bungyoku; Sohei Kitazawa; Satoshi Ishido; Ikuo Shoji; Hak Hotta
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.